A recent study correlated the presence of the AIM2 inflammasome complex signature with drug sensitivity to the compounds AICAR, AT-7519, bosutinib, DMOG, and Z-LLNLE-CHO [15], suggesting a potential therapy for these tumour types. The gene discussed is AIM2; the disease is neoplasm.